Avalanche Biotechnologies to Participate in Gene Therapy Panel at the BIO Investor Forum
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit www.avalanchebiotech.com.
CONTACT: Investor Contact:
Chris Erdman MacDougall Biomedical Communications(781) 235-3060 firstname.lastname@example.org Media Contact: Kathy Vincent(310) 403-8951 email@example.com